Document is current
Any future updates will be listed below
-
Authors
Chan, Jason E. https://orcid.org/0000-0003-0552-8544
Pan, Chun-Hao
Rub, Jonathan
Guzman, Gary
Krause, Klavdija
Brown, Emma
Zhang, Zeda https://orcid.org/0000-0002-7225-534X
Styers, Hannah https://orcid.org/0009-0007-9339-4254
Hartmann, Griffin https://orcid.org/0000-0001-9213-8995
Li, Zhuxuan
Zhuang, Xueqian https://orcid.org/0000-0001-7012-3223
Lowe, Scott W. https://orcid.org/0000-0002-5284-9650
Betel, Doron https://orcid.org/0000-0002-8006-7752
Yan, Yan https://orcid.org/0000-0001-9859-3593
Tammela, Tuomas https://orcid.org/0000-0003-3675-6961
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 1 December 2025
First Online: 21 January 2026
Competing interests
: T.T. is a scientific advisor with equity interests in Lime Therapeutics. His spouse is an employee of and has equity in Recursion Pharmaceuticals. The Tammela laboratory receives funding from Ono Pharma related to targeting the HPCS, although this funding did not directly support this work. S.W.L. is a consultant and holds equity in Blueprint Medicines, ORIC Pharmaceuticals, Mirimus, PMV Pharmaceuticals, Faeth Therapeutics and Senecea Therapeutics, and is a consultant for Fate Therapeutics. S.W.L. has equity in a joint venture developed by MSKCC and a cell therapy company to develop senolytic cell-based therapies for non-cancer indications. The company has licensed MSKCC IP, including hUPAR binders. The Mark Foundation provided the Endeavor Award to Scott Lowe for “Harnessing Senescence Biology for Immune Oncology”. The other authors declare no competing interests.
